Cancer Genetics Inc. (CGIX) Reaches New 12-Month Low at $1.80
Cancer Genetics Inc. (NASDAQ:CGIX) shares reached a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $1.80 and last traded at $2.01, with a volume of 107,422 shares. The stock had previously closed at $2.16.
Separately, Zacks Investment Research lowered shares of Cancer Genetics from a “buy” rating to a “hold” rating in a research report on Monday, May 16th.
The stock has a 50-day moving average of $2.04 and a 200-day moving average of $2.33. The firm’s market capitalization is $26.35 million.
Cancer Genetics (NASDAQ:CGIX) last announced its earnings results on Wednesday, August 10th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.05. During the same quarter in the previous year, the firm earned ($0.51) earnings per share. The company had revenue of $7 million for the quarter, compared to the consensus estimate of $6.50 million. The company’s revenue for the quarter was up 67.3% compared to the same quarter last year. On average, equities research analysts expect that Cancer Genetics Inc. will post ($1.26) EPS for the current fiscal year.
Cancer Genetics, Inc is engaged in the field of personalized medicine, enabling precision medicine in the field of oncology through its diagnostic products and services, and molecular markers. The Company develops, commercializes and provides molecular- and biomarker-based tests and services that enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment, and enable biopharmaceutical companies engaged in oncology trials to select candidate populations and manage adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.